Mayo Clinic Laboratories’ BioPharma Diagnostics team facilitates customized collaborations with diagnostic companies to support their clinical and research testing needs.
Confirmatory testing - Insights
Use of mass spectrometry technology in Mayo Clinic Laboratories’ confirmatory drug testing enables accurate identification of parent drugs and metabolites, equipping providers with confidence about their patients’ drug use.
Outreach Quality and Satisfaction - The Patient's View - Insights
As healthcare continues to evolve and payment models become more inclusive of patient satisfaction measures, it is vitally important for laboratories to focus on improving the patient experience. Because the laboratory is a critical element...
Jessica Wright, Pharm.D., BCACP, explains how Mayo Clinic Laboratories' 3A5Q test helps determine initial tacrolimus doses for individuals after non-liver organ transplants. Optimal tacrolimus levels are one of the important factors in...
Hereditary Oncology Testing [Test in Focus] - Insights
Wei Shen, Ph.D., explains Mayo Clinic Laboratories' new expert-backed, hereditary oncology panels, which use next-generation sequencing to identify genetic mutations linked to increased cancer risk. By only including clinically significant...
Newborn Screening at Mayo Clinic Laboratories
Newborn screening is intended to detect serious health conditions in babies for which early intervention can greatly improve healthy development and positive outcomes.
New tests launched in November - Insights
In November 2022, Mayo Clinic Laboratories announced eighteen new tests along with numerous reference value changes, obsolete tests, and algorithm changes.
Novel panel identifies toxins linked to asthma and GI diseases - Insights
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of...
Assay enhances and simplifies M-proteins screening: David Murray, M.D., Ph.D. - Insights
David Murray, M.D., Ph.D., explains how Mayo Clinic Laboratories' MASS-FIX Quantitation assay provides next-generation screening for M-proteins, which are associated with multiple myeloma and other diseases. The assay better quantitates the...
Clinical and forensic toxicology - Insights
Clinical, forensic, and emergency toxicology testing at Mayo Clinic Laboratories, which aligns with evidence-based clinical laboratory guidelines, uses advanced and emerging technologies and is performed on urine, serum, and meconium...
Neurofascin 155 IgG4 Antibody Test [Test in Focus] - Insights
John Mills, Ph.D., explains Mayo Clinic Laboratories' new neurofascin 155 (NF155) IgG4 antibody test, which is the first commercially available test in the U.S. to use flow cytometry to detect for NF155 antibodies and confirm diagnosis of...
Autoimmune Myelopathy Testing - Mayo Clinic Laboratories
Mayo Clinic Laboratories is the only laboratory in the world to offer testing for a novel form of autoimmune meningoencephalomyelitis.
We offer next-generation sequencing and comprehensive fluorescence in situ hybridization (FISH) panels, as well as extensive immunohistochemistry (IHC) offerings, to diagnose and monitor T-cell lymphoma.
Learn about our comprehensive MayoComplete solid tumor panel, which analyzes 515 genes for mutations, rearrangements, and amplifications.
Lung Cancer NGS Panel - Mayo Clinic Laboratories
Our targeted lung cancer panel assesses for mutations in eight genes, and rearrangements in four genes, including those recommended by the National Comprehensive Cancer Network: EGFR, ROS1, BRAF, and ALK.
Browse our menu of MayoComplete next-generation sequencing assays which are designed to identify a growing list of hematological cancers.
Thrombotic microangiopathy (TMA) - Insights
View our comprehensive testing suite designed to confirm diagnosis and facilitate treatment of thrombotic microangiopathy.
Find out how our streamlined approach to fluorescence in situ hybridization testing can simplify the ordering process and better meet patient needs.
Mayo Clinic researchers identify new disease subtype linked to recurrent blood clots - Insights
Mayo Clinic researchers identify a new subtype of MGTS, linked to recurrent blood clots, with significant diagnostic challenges and treatment implications.
Testing Archives - Page 25 of 26 - Insights
Skip to Content MayoACCESS MayoLINK...
New Tests Launched Archives - Page 5 of 6 - Insights
Skip to Content MayoACCESS MayoLINK...
Dr. Dong Chen and Dr. Sounak Gupta joined the “Becker’s Healthcare Podcast” to discuss the molecular testing space and its important role in personalized cancer treatment. Dr. Chen and Dr. Gupta highlighted the importance of selecting the...
Testing Archives - Page 13 of 26 - Insights
Skip to Content MayoACCESS MayoLINK...
The newsroom features stories of Mayo Clinic Laboratories and its experts in the news. For media inquiries and expert interviews, contact the Media Relations Newsroom at newsbureau@mayo.edu, attention: Mayo Clinic Laboratories.
The Importance of Sales Call Planning in Laboratory Outreach Sales - Insights
Sales is a vital component of a thriving laboratory outreach program. It requires a unique skill set and a dedicated focus on advocating the value of your laboratory and its ability to deliver reliable, high-quality services to your...
Practical Approaches to Outreach Marketing - Insights
Marketing is an essential discipline of any successful laboratory outreach program. While specific marketing goals and audiences will differ for every program, most of them will certainly involve driving awareness and growth. A strong...
Managing Operational Surprises in Real Time - Insights
While preparation is key to mitigating risk, inevitably, there are unforeseen circumstances that will impact operations. Here are four ways the outreach laboratory can swiftly manage operational surprises in real time.
Preparing a customer performance update report - Insights
Depending on the types of specimens that are referred to the outreach laboratory, there may be an opportunity to share a customer performance update report with the client so that they can align with, or even develop their own laboratory...
The Expanding Reach of the Laboratory Outreach Program - Insights
The most successful laboratory outreach programs recognize the importance of serving multiple customers. From provider to patient to healthcare consumer, the laboratory has an opportunity to serve them all with high-quality results and...
Thrombotic Microangiopathies (TMA) [Test in Focus] - Insights
Meera Sridharan, M.D., Ph.D., explains Mayo Clinic Labs’ testing approach for atypical hemolytic uremic syndrome (aHUS). The serological complement panel examines nine analytes to gain a thorough understanding of the complement cascade to...
The assay is now recommended for diagnosing and monitoring patients with monoclonal protein disorders and exclusively available through Mayo Clinic Laboratories– Rochester.
Meet Me at the Microscope at USCAP 2020 - Insights
Mayo Clinic pathologists, researchers, and a wide spectrum of allied health staff will be in Los Angeles, California, for the 109th United States and Canadian Academy of Pathology Meeting (USCAP). Visit us at booth #716 on March 2 - 4, 2020...
Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test...
Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of...
Mayo Clinic Laboratories easily consumable content, ensuring knowledge retention in minimal time. These microlearning educational offerings will cover a variety of topics relevant to current and aspiring laboratory leaders.
Matthew J. Schultz, Ph.D., and Amy L. White, M.S., CGC, explain how Mayo Clinic Laboratories' unique urine assay (Mayo ID: SORD) screens for peripheral neuropathy arising from SORD gene variants. Although recently identified, SORD-related...
Disaccharidase Activity Panel [Test in Focus] - Insights
Pua Hopson, D.O., discusses Mayo Clinic Labs’ new disaccharidase activity panel, which measures levels of five digestive enzymes to identify deficiencies that cause carbohydrate maldigestion and can lead to chronic conditions like celiac...
Mayo Clinic Laboratories and KYAN Technologies announced a collaboration to validate and provide the KYAN test, Optim.AI™, across the United States.
Maria Willrich, Ph.D., and Melissa Snyder, Ph.D., describe Mayo Clinic Laboratories' panel for proactive therapeutic drug monitoring of patients with inflammatory bowel disease. The panel expands options for clinicians assessing patients'...
Testing aids nicotine-use cessation: Paul Jannetto, Ph.D. - Insights
Tobacco use is the leading cause of preventable death in the United States. In this test-specific episode of the "Answers From the Lab" podcast, Paul Jannetto, Ph.D., explains how Mayo Clinic Laboratories' nicotine testing benefits patients...
New Panels Help Find Cause of Rapidly Progressive Dementia: Gregg Day, M.D. - Insights
Rapidly progressive dementia (RPD) is an umbrella term covering many devasting conditions, including Creutzfeldt-Jakob disease (CJD). Gregory (Gregg) Day, M.D., explains how Mayo Clinic Laboratories' unique RPD evaluation and new CJD test...
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating...
Divyanshu Dubey, M.B.B.S., explains how Mayo Clinic Laboratories' unique PDE10A and TRIM46 tests facilitate the management of central nervous system disorders triggered by cancers. Early diagnosis and treatment are important for managing...
State-of-the-art genetics panel optimizes kidney disease treatment - Insights
Linnea M. Baudhuin, Ph.D., and Emily K. Thoreson, M.S., CGC, explain how Mayo Clinic Laboratories renal genetics testing provides comprehensive, accurate and actionable results. Identifying a genetic cause helps guide the complex decisions...
Hypermethylation Test Guides Lynch Syndrome Care: Megan Hoenig, M.S., M.P.H., CGC - Insights
Megan Hoenig, M.S., M.P.H., CGC, explains how Mayo Clinic Laboratories' unique hypermethylation analysis (Mayo ID: MLHPB) provides critical adjunct information for managing Lynch syndrome. That genetic condition increases the risk for many...
Genetic Tests Identify Risk of Fluoropyrimidine-Induced Toxicity: Ann Moyer, M.D., Ph.D. - Insights
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for...
Assay identifies rare tick-borne bacteria: Bobbi Pritt, M.D. - Insights
Bobbi Pritt, M.D., explains how Mayo Clinic Laboratories' new assay identifies less-common tick-borne bacteria in whole blood. The assay is recommended when tick-borne bacterial infection is suspected but standard testing is unrevealing.
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' gynecological NGS panels provide focused assessments of gynecological cancers. The cost-effective tests fill the gap between single gene assays and large cancer panels,...
Robert Jenkins, M.D., Ph.D., Stephanie Smoley, CG(ASCP), and Beth Pitel, M.S., explain how Mayo Clinic Laboratories' enhanced MayoComplete Solid Tumor Panel better profiles tumor genetics. Defining tumor pathogenesis can guide targeted...
Mayo Clinic Laboratory and Pathology Research Roundup: Sept. 24 - Insights
This week’s Research Roundup highlights the limitations of platform assays to measure serum 25OHD level impact on guidelines and practice decision-making.